Hertfordshire, England – Mylan and Pfizer announced that the U.S. Federal Trade Commission accepted a proposed consent order, which concludes the FTC’s review of the proposed combination of Mylan and Pfizer’s Upjohn Business. The parties have now obtained all required antitrust clearances for the proposed transaction. The combination will be effected through a Reverse Morris
HERTFORDSHIRE, England— Mylan and Upjohn, a division of Pfizer, unveiled on Thursday the logo and branding for Viatris, the new company that will be formed by combining Mylan and Upjohn. Viatris will benefit from Mylan and Upjohn’s trusted global offerings and legacy of meeting patient needs around the world. The new logo and branding is
HERTFORDSHIRE, England – Mylan announced that its shareholders overwhelmingly voted to approve the proposed transaction combining Mylan and Upjohn, a division of Pfizer, at the company’s extraordinary general meeting of shareholders. Approximately 99.6% of votes cast were voted in favor of the combination. Mylan executive chairman and future Viatris executive chairman Robert Coury said: “The
NEW YORK— Pfizer and Mylan announced Monday a definitive agreement to combine Mylan with Upjohn, Pfizer’s off-patent branded and generic established medicines business, creating a new global pharmaceutical company. Under the terms of the agreement, which is structured as an all-stock, Reverse Morris Trust transaction, each Mylan share would be converted into one share of
